Sign inJoin waitlistJoin the waitlist

Brian Boulmay

Fellowship Program Director · Louisiana State University School of Medicine

Credentials: · · · · · ·

History

Louisiana State University School of Medicine Fellowship
Present
Louisiana State University School of Medicine
Present
Louisiana State University School of Medicine
Present

Hematology and Medical Oncology
2005–2008
Internal Medicine
University of Florida
2002–2005
Louisiana State University and Agricultural & Mechanical College
1998–2002

Research

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
Journal of Clinical Oncology · 2019 · 300 citations
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
Journal for ImmunoTherapy of Cancer · 2021 · 118 citations
Small cell lung cancer: time to diagnosis and treatment
Southern Medical Journal · 2012 · 17 citations

Adam Riker
3 papers
Adil Daud
2 papers
AB
Andrew Brohl
2 papers
Brent Hanks
2 papers · 2 as a resident
ES
Elad Sharon
2 papers
EL
Evan Lipson
2 papers
Harriet Kluger
2 papers
Janis Taube
2 papers
MC
Martin Cheever
2 papers
MB
Melissa Burgess
2 papers
Michi Shinohara
2 papers
Paul Nghiem
2 papers

Clinical trials

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2039
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2023–2036
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Site PI · Recruiting
SWOG Cancer Research Network
2021–2028
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2020–2027